Sensus Healthcare, Inc.

NASDAQ:SRTS

Medical - Devices

Healthcare
$3.22 +3.05%

+$0.09 today

Market cap
$53.01M
Beta
1.09
P/E (TTM)
-6.5
EPS (TTM)
-$0.47
52W Low $2.66High $5.92

Volume 0.08M

Average 0.06M

SRTS Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Sensus Healthcare, Inc.NASDAQ: SRTS

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow growth accelerates

Q1 FY2026 free cash flow of $3.76M (cash outflow) rose 39.9% year over year, ahead of the -116.0% change in trailing-twelve-month free cash flow. Sequentially, it rose 58.8% from the prior quarter.

Context

  • Free cash flow amounted to 1.2% of revenue in FY2025, down 1.4 pp from a year earlier.
  • Free cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +39.9% holds above the trailing-twelve-month pace of -116.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.76M+58.8% QoQ
Last fiscal yearDec 2025
$332K+130.0% YoY
LTMMar 2026
-$740K-116.0% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+39.9%——
1 year+130.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
332K USD
Year-over-year change
+130.0%

Free Cash Flow vs competitors

How SRTS compares with its peers on the latest reported figures

  • SRTS's LTM Mar 2026 free cash flow of $740K is the smallest of the 6 companies compared; the peer median is $31.62M.
  • Its year-over-year change of -116.0% is the lowest of 6, against a peer median of -16.0%.
  • Free cash flow amounts to 3.3% of revenue for SRTS, versus a peer median of 39.3%.
SRTS Competitors Peer median
Free Cash Flow for SRTS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IPSCCentury Therapeutics, Inc.LTM Mar 2026$95.91M -16.0%+85.0%—
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$59.11M -51.8%-20.4%39.1%
TELATELA Bio, Inc.LTM Jun 2026$31.62M -8.8%-12.4%39.6%
MDAISpectral AI, Inc.LTM Mar 2026$12.14M +51.3%+104.4%72.7%
BDMDBaird Medical Investment Holdings LimitedFY2025$1.39M -84.9%-36.7%6.2%
SRTSSensus Healthcare, Inc.LTM Mar 2026$740K -116.0%—3.3%
Peer median (excluding SRTS) $31.62M-16.0%-12.4%39.3%

Competitors are the stored peer set for SRTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income4.12M24.24M485K6.65M(7.72M)
Depreciation & Amortization613K509K461K432K626K
Deferred Income Tax0(1.71M)(427K)(57K)(1.88M)
Stock-Based Compensation415K187K328K323K295K
Change in Working Capital(6.14M)(12.92M)(3.56M)(8.55M)8.66M
Accounts Receivables(8.43M)(5.31M)6.65M(9.21M)13.65M
Inventory2.74M(3.19M)(8.58M)268K(4.64M)
Accounts Payables962K799K(2.73M)2.02M(1.47M)
Other Working Capital(1.4M)(5.22M)1.1M(1.63M)1.12M
Other Non-Cash Items705K(11.72M)568K378K547K
Operating Cash Flow(286K)(1.41M)(2.15M)(831K)528K
Capital Expenditures(128K)(159K)(229K)(276K)(196K)
Acquisitions (Net)257K15M000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0042K00
Investing Cash Flow129K14.84M(187K)(276K)(196K)
Debt Repayment(216K)(51K)000
Common Stock Issued00067K0
Common Stock Repurchased(15K)(3M)(27K)0(300K)
Dividends Paid00000
Other Financing Activities0622K(13K)(52K)(5K)
Financing Cash Flow(231K)(2.43M)(40K)15K(305K)
Effect of Forex Changes00000
Net Change in Cash(388K)11M(2.37M)(1.09M)27K
Free Cash Flow(414K)(1.57M)(2.37M)(1.11M)332K

Sensus Healthcare, Inc.

NASDAQ:SRTS

Intrinsic Alpha fair value

Locked

Current Price

$3.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.